Suggestions
Fred Middleton
Founder and Managing Director at Sanderling Ventures
Fred Middleton is a highly experienced and accomplished figure in the biotechnology and biomedical industries, with over 35 years of experience in both corporate operating management and institutional venture capital investing. Here are key details about his career and background:
Career Highlights
Sanderling Ventures
Fred Middleton is the Founder and Managing Director of Sanderling Ventures, a biomedical venture capital firm he joined in November 1987.2 At Sanderling, he has:
- Focused on initial active management and investment in early-stage biomedical technology companies
- Served as Managing Director for Sanderling Funds II (1988) through VII (2013)
- Worked as an investor, management team member, and director in over 25 new biomedical ventures1
Previous Experience
Genentech: From July 1978 to 1985, Middleton was a member of the startup management team at Genentech, a pioneering biotech company.2 His roles included:
- Vice President of Finance and Corporate Development
- Chief Financial Officer
- Managed multiple financings, including Genentech's successful IPO in October 1980
Other Notable Positions:
- Chairman and Chief Business Officer at Altor Bioscience Corporation (2005-2017)2
- Director at BioTelemetry, Inc. (formerly CardioNet) (2000-2011)2
- Founder of Morgan Stanley Ventures (1984)1
Education
- Bachelor of Science in Chemistry from Massachusetts Institute of Technology (1967-1971)2
- MBA in Finance and Entrepreneurship from Harvard Business School (1971-1973)2
Achievements and Contributions
- Co-founded Sanderling Ventures with Dr. Robert McNeil in 1987
- Raised over $1.1 Billion in start-up capital investments since 1979
- Played key roles in numerous biotech companies, including Regeneron Pharmaceuticals, Pacira Pharmaceuticals, and Stereotaxis1
- Elected as a member of the M.I.T. Corporation (board of trustees) in 20071
Fred Middleton's extensive experience and success in both corporate management and venture capital have made him a prominent figure in the biomedical and biotechnology industries.
